SEC Form 4 · accession 0001522780-26-000007
Stoke Therapeutics, Inc. · STOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward M. Kaye M.D.
Director
Period of report
Aug 14, 2026
Accepted (ET)
Aug 18, 2026 · 8:28 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001623526
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 14, 2026 | M | 26,250 | $0.00 | A | 137,124 | D | |
| Common StockF2 | Aug 18, 2026 | S | 11,930 | $32.0072 | D | 125,194 | D | |
| Common StockF3 | Aug 18, 2026 | S | 637 | $32.4681 | D | 124,557 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Stock UnitsF4,F5 | — | Aug 14, 2026 | M | 26,250 | D | — | Aug 14, 2026 | Common Stock | 26,250 | 0 | D |
Explanation of responses
- F1The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
- F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.
- F4Each performance stock unit represents a right to receive one share of the Issuer's common stock.
- F5Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.